Conducting clinical trials of deep brain stimulation in Parkinson's disease

Deep Brain Stimulation for Parkinson's Disease

Volumn , Issue , 2007, Pages 299-322

  Weaver, Frances M ^a   Follett, Kenneth A ^b   Reda, Domenic J ^c   Hur, Kwan ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960569827     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (54)

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312(7023):71-72.
2. Gray GE. Evidence-based medicine: an introduction for psychiatrists. J Psychiatr Pract2002; 8(1):5-13.
3. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95(suppl 2):2S-4S.
4. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62(2):241-248.
5. Schneider E. DATATOP-study: significance of its results in the treatment of Parkinson's disease. J Neural Transm Suppl 1995; 46:391-397.
6. Weaver F, Follett K, Hur K, et al. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 2005; 103(6):956-967.
7. Follett K, Weaver F, Stern M, et al. VA Cooperative Study #468. A comparison of best medical therapy and deep brain stimulation of subthalamic nucleus and globus pallidus for the treatment of Parkinson's disease. Study Protocol. Cooperative Studies Program, Research & Development Service, Department of Veterans Affairs, Washington, D.C., October 1, 2001.
8. Vitek JL. Deep brain stimulation for Parkinson's disease. A critical re-evaluation of STN versus GPi DBS. Stereotact Funct Neurosurg 2002; 78(3-4):119-131.
9. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128:2240-2249.
10. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349(20):1925-1934.
11. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, eds. Recent developments in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information 1987:153-164.
12. Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation inpatients with Parkinson disease. J Neurosurg 2005; 103(2):252-255.
13. Okun M. Effects of deep brain stimulation on motor, mood, and cognitive symptoms in Parkinson's disease. University of Florida, Gainesville, FL. http://www.pdtrials.org/trial_detail_print.php?trial_id=333 (accessed January 2006).
14. Deuschl G. The effect of deep brain stimulation compared with best medical treatment on life quality in Parkinson's disease: arandomized controlled multi-center study. The 16th International Congress on Parkinsonism and Related Disorders. Berlin. June 8, 2005.
15. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76(12):1640-1644.
16. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994; 9(1):76-83.
17. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7(1):2-13.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17(5):427-442.
19. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. Third symposium on Parkinson's disease. Edinburgh: Gillingham and Donaldson, 1969.
20. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004; 19(12):1409-1413.
21. Nyholm D, Kowalski J, Aquilonius SM. Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease. Mov Disord 2004; 19(4):446-451.
22. Lezcano E, Gomez-Esteban JC, Zarranz JJ, et al. Improvement in quality of life in patients with advanced Parkinson's disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol 2004; 11(7):451-454.
23. Parkinson Alliance. Focus 1 Report DBS/STN Patient Survey on Pre and Post Surgery Symptoms. January 2004.
24. De Boer AG, Wijker W, Speelman JD, et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996; 61(1):70-74.
25. Van den Berg M. Leben mit Parkinson: Entwicklung und psychometrische Testung des Fragenbogens PLQ. Neurol Rehabil 1998; 4:221-226.
26. Calne S, Schulzer M, Mak E, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson's impact scale. Parkinsonism Relat Disord 1996; 2:55-61.
27. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245(suppl 1):S10-S14.
28. Marinus J, Ramaker C, van Hilten JJ, et al. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002; 72(2):241-248.
29. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473-483.
30. Pahwa R, Wilkinson SB, Overman J, et al. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg 2003; 99(1):71-77.
31. Ehrt U, Aarsland D. Psychiatric aspects of Parkinson's disease. Curr Opin Psychiatry 2005; 18(3):335-341.
32. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19(9):1043-1049.
33. Lauterbach EC. The neuropsychiatry of Parkinson's disease. Minerva Med 2005; 96(3):155-173.
34. Fields JA, Troster AI, Wilkinson SB, et al. Cognitive outcome following staged bilateral pallidal stimulation for the treatment of Parkinson's disease. Clin Neurol Neurosurg 1999; 101(3):182-188.
35. Fields JA, TrosterAI. Cognitive outcomes afterdeep brain stimulation forParkinson's disease: a review of initial studies and recommendations for future research. Brain Cogn 2000; 42(2):268-293.
36. Rodriguez RL, Miller K, Bowers D, et al. Mood and cognitive changes with deep brain stimulation. What we know and where we should go. MinervaMed 2005; 96(3): 125-144.
37. Taylor AE, Saint-Cyr JA. The neuropsychology of Parkinson's disease. Brain Cogn 1995; 28(3):281-296.
38. Mattis S. Dementia Rating Scale: Professional Manual. Psychological Assessment Resources Inc, Odessa, Florida, 1973.
39. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3):189-198.
40. Brown G, Rahill A, Gorell J, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999; 12(4):180-188.
41. Trepanier LL, Saint-Cyr JA, Lozano AM, et al. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. Neurology 1998; 51(1):207-215.
42. Hariz MI. Complications of deep brain stimulation surgery. Mov Disord 2002; 17(suppl 3):S162-S166.
43. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16(1):59-69.
44. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001; 57(4):663-671.
45. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997; 45(7):844-849.
46. McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease. Mov Disord 2003; 18(9):993-999.
47. Gold MR, Russell LB, Seigel JE, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
48. Burchiel KJ, Anderson VC, Favre J, et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 1999; 45(6):1375-1382.
49. Anderson VC, Burchiel KJ, Hogarth P, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005; 62(4):554-560.
50. PD SURG Trial-A large randomised assessment of the relative cost-effectiveness of surgery for Parkinson's disease. Protocol Version 2 (November 21,2001). Birmingham Clinical Trials Unit, University of Birmingham.
51. Vitek JL, DeLong MR. Deep brain stimulation for Parkinson's disease trial. http://www.clinicaltrials.gov/ct/show/NCT00053625 (accessed March 2006).
52. Okun M. The MOST study: Mood and STN DBS. University of Florida, Gainesville, FL. http://www.pdtrials.org/trial_detail_print.php7trial_id=332 (accessed January 2006).
53. Charles PD. DBS in early stage Parkinson's disease. http://www.clinicaltrials.gov/ct/show/NCT00282152 (accessed March 2006).
54. Schadt CR, Charles PD. Effect of deep brain stimulation on depression and quality of life in Parkinson's patients. http://www.clinicaltrials.gov/ct/show/NCT00179101 (accessed March 2006).